Summary: Increased blood brain barrier permeability may be a key mechanism in the early stages of Alzheimer’s disease, a new study reports.
Researchers using contrast-enhanced MRI have identified leakages in the blood-brain barrier (BBB) of people with early Alzheimer’s disease (AD), according to a new study published online in the journal Radiology. The results suggest that increased BBB permeability may represent a key mechanism in the early stages of the disease.
The BBB, a collection of cells and subcellular structures in the cerebrovascular wall that separates the circulating blood from the brain, is essential to keep brain tissue in healthy condition. It regulates the delivery of important nutrients and blocks neurotoxins, while removing surplus substances from the brain.
For the study, researchers used contrast-enhanced MRI to compare 16 early AD patients with 17 healthy age-matched controls. They measured BBB leakage rates and generated a map called a histogram to help determine the amount of the leaking brain tissue.
The BBB leakage rate was significantly higher in AD patients compared with controls and the leakage was distributed throughout the cerebrum, the largest part of the brain. AD patients had a significantly higher percentage of leaking brain tissue in the gray matter, including the cortex, the brain’s outer layer. The researchers also found that measurements derived from the histogram showed very subtle BBB impairment in the brain’s white matter.
“Blood-brain barrier leakage means that the brain has lost its protective means, the stability of brain cells is disrupted and the environment in which nerve cells interact becomes ill-conditioned,” said study author Walter H. Backes, Ph.D., from the Maastricht University Medical Center in Maastricht, the Netherlands. “These mechanisms could eventually lead to dysfunction in the brain.”
Indeed, the researchers found a relationship between the extent of BBB impairment and decline in cognitive performance, suggesting that a compromised BBB is part of the early pathology of AD and might be part of a cascade of events eventually leading to cognitive decline and dementia.
The connection between BBB impairment and AD pathology was strengthened by the fact that the addition of diabetes and other non-cerebral vascular diseases to the analysis model did not change the results.
According to Dr. Backes, the key advantage of detecting BBB leakage with contrast MRI is that it can detect early microvascular changes in AD even in cases where no directly visible cerebrovascular abnormalities can be observed.
“For Alzheimer’s research, this means that a novel tool has become available to study the contribution of blood-brain barrier impairment in the brain to disease onset and progression in early stages or pre-stages of dementia,” he said.
Funding: The study was funded by Internationale Stichting Alzheimer Onderzoek.
Source: Linda Brooks – RSNA
Image Source: This NeuroscienceNews.com image is in the public domain.
Original Research: Full open access research for “Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease” by Harm J. van de Haar, MSc, Saartje Burgmans, PhD, Jacobus F. A. Jansen, PhD, Matthias J. P. van Osch, PhD, Mark A. van Buchem, MD, Majon Muller, MD, Paul A. M. Hofman, MD, Frans R. J. Verhey, MD, and Walter H. Backes, PhD in Radiology. Published online May 31 2016 doi:10.1148/radiol.2016152244
[cbtabs][cbtab title=”MLA”]RSNA. “Leaky Blood-Brain Barrier Linked to Alzheimer’s.” NeuroscienceNews. NeuroscienceNews, 31 May 2016.
<https://neurosciencenews.com/bbb-alzheimers-neurology-4346/>.[/cbtab][cbtab title=”APA”]RSNA. (2016, May 31). Leaky Blood-Brain Barrier Linked to Alzheimer’s. NeuroscienceNews. Retrieved May 31, 2016 from https://neurosciencenews.com/bbb-alzheimers-neurology-4346/[/cbtab][cbtab title=”Chicago”]RSNA. “Leaky Blood-Brain Barrier Linked to Alzheimer’s.” https://neurosciencenews.com/bbb-alzheimers-neurology-4346/ (accessed May 31, 2016).[/cbtab][/cbtabs]
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
To investigate whether the blood-brain barrier (BBB) leaks blood-circulating substances in patients with early forms of Alzheimer disease (AD), and if so, to examine the extent and pattern of leakage.
Materials and Methods
This study was approved by the local medical ethical committees of the Maastricht University Medical Center and Leiden University Medical Center, and written informed consent was obtained from all subjects. For this pilot study, 16 patients with early AD and 17 healthy age-matched control subjects underwent dynamic contrast material–enhanced magnetic resonance (MR) imaging sequence with dual time resolution for 25 minutes. The Patlak graphical approach was used to quantify the BBB leakage rate and local blood plasma volume. Subsequent histogram analysis was used to determine the volume fraction of the leaking brain tissue. Differences were assessed with linear regression analysis, adjusted for confounding variables.
The BBB leakage rate was significantly higher in patients compared with that in control subjects in the total gray matter (P < .05) and cortex (P = .03). Patients had a significantly higher volume fraction of the leaking brain tissue in the gray matter (P = .004), normal-appearing white matter (P < .04), deep gray matter (P = .01), and cortex (P = .004). When all subjects were considered, scores on the Mini-Mental State Examination decreased significantly with increasing leakage in the deep gray matter (P = .007) and cortex (P < .05).
The results of this study showed global BBB leakage in patients with early AD that is associated with cognitive decline. A compromised BBB may be part of a cascade of pathologic events that eventually lead to cognitive decline and dementia.
“Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease” by Harm J. van de Haar, MSc, Saartje Burgmans, PhD, Jacobus F. A. Jansen, PhD, Matthias J. P. van Osch, PhD, Mark A. van Buchem, MD, Majon Muller, MD, Paul A. M. Hofman, MD, Frans R. J. Verhey, MD, and Walter H. Backes, PhD in Radiology. Published online May 31 2016 doi:10.1148/radiol.2016152244